Please login to the form below
Emma Walmsley
This page shows the latest Emma Walmsley news and features for those working in and with pharma, biotech and healthcare.
GSK beats expectations thanks to strong vaccine sales in Q2
range for 2021, and meaningful performance improvement in 2022,” said Emma Walmsley, chief executive officer of GSK. ... In response, GSK’s board said that it ‘strongly believes’ that Walmsley is the ‘right leader’ for the new biopharma
Latest news
-
GSK reveals plans for £400m R&D facility expansion in England
Last month, GSK unveiled its ten-year strategy, with chief executive officer Emma Walmsley revealing the company is expecting product sales to reach £33bn ($46bn) by 2031. ... Walmsley has come under increasing pressure to improve GSK’s performance
-
GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
GSK’s board said that it ‘strongly believes’ Walmsley is the ‘right leader’ for the new biopharma business. ... In response to a 17-page letter from activist hedge fund Elliott Management last week, GlaxoSmithKline (GSK) has thrown its support
-
Elliott Management puts pressure on GSK after years of ‘disappointing performance’
Although GSK’s chief executive officer Emma Walmsley was not named, Elliott highlighted ‘leadership failures’ regarding the company’s plans for the consumer health/biopharma separation.
-
UK government ‘concerned’ over Elliott Management’s plans for GSK
According to The Times, Britain’s Secretary of State for Business, Energy and Industrial Strategy is believed to have asked government officials to back GSK’s chief executive officer Emma Walmsley – ... Walmsley has come under increasing pressure
-
GSK’s revenue drops by 18% in Q1 as performance pressures mount
Chief executive Emma Walmsley said results ‘reflect the anticipated impacts of COVID-19’. ... GlaxoSmithKline (GSK) has announced that its first quarter sales have slipped by 18%, with the company's chief executive Emma Walmsley maintaining that the
GSK reveals plans for £400m R&D facility expansion in England
GSK supports CEO Emma Walmsley following Elliott's demands for leadership overhaul
More from news
Approximately 2 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Women Leaders in UK Healthcare: Liz Henderson
It’s also great to see outside Merck that women are also progressing in other companies too – like Emma Walmsley at GSK – which gives women the inspiration that they too can
-
25 Women Leaders in UK Healthcare
10. THEODORA HAROLD . Biotech leader. While big pharma is making some significant strides in having women as their top leaders (most notably GSK’s CEO Emma Walmsley), the biotech sector, particularly
-
Diversity and inclusion in the pharma industry
If, as GlaxoSmithKline CEO Emma Walmsley said, talking about diversity to Business Insider UK, ‘‘You cannot be a modern employer in an industry that should be future facing and modernising arguably
-
30 Women Leaders in UK Healthcare (part 3)
29. Emma Walmsley, GSK CEO. Emma Walmsley is the first-ever woman leader of a big pharma company, having taken on the CEO role at GlaxoSmithKline in April 2017. ... Since then, Walmsley has very definitely put her own stamp on the firm, making major
-
Pharma deals continue to slide
Emma Walmsley, CEO of GSK, said: “We will use cash for business development purposes, with M&A obviously dependent on the right kind of return profile.”.
Women Leaders in UK Healthcare: Liz Henderson
25 Women Leaders in UK Healthcare
Diversity and inclusion in the pharma industry
Pharma deals continue to slide
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
GSK appoints president of global pharmaceuticals
Emma Walmsley, GSK's chief executive officer designate, said: “Luke brings a combination of excellent R&D insight and a strong track record of commercial execution.
GSK appoints president of global pharmaceuticals
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Future of MHRA uncertain amid Brexit-fuelled shake up
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- David Hunt launches independent agency The Considered
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Accelerating Drug Development Timelines with Big Data Analytics
- A Lucid Group Thirsty Thursday Special: Beautiful Rejects
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US orders 1.4 million more doses of Regeneron antibody cocktail
- Taking centre stage: the role of behaviour change initiatives in the management of long-term conditions
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- Live Webinar: Making Actionable Health Information More Accessible Through Point-of-Care Testing
- Ovid wins Communiqué Small Consultancy of the Year award at Communiqué 2021
- Future of MHRA uncertain amid Brexit-fuelled shake up
- Lucid Group celebrates a double win at Communiqué 2021
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
